Athersys (ATHX) Given Daily Coverage Optimism Score of 0.20

News coverage about Athersys (NASDAQ:ATHX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Athersys earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.3989536913056 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Athersys (NASDAQ:ATHX) traded down $0.07 during trading hours on Thursday, hitting $1.90. The stock had a trading volume of 752,400 shares, compared to its average volume of 674,345. Athersys has a one year low of $1.02 and a one year high of $2.63. The firm has a market cap of $223.44, a P/E ratio of -7.31 and a beta of -0.38.

Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). Athersys had a negative return on equity of 113.63% and a negative net margin of 746.04%. analysts anticipate that Athersys will post -0.25 earnings per share for the current year.

A number of equities research analysts have recently commented on ATHX shares. ValuEngine downgraded Athersys from a “hold” rating to a “sell” rating in a research report on Tuesday, December 5th. Maxim Group set a $12.00 price objective on Athersys and gave the company a “buy” rating in a research report on Thursday, November 16th. Finally, Zacks Investment Research downgraded Athersys from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $7.17.

In other news, COO William Lehmann, Jr. sold 14,000 shares of the stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $1.80, for a total transaction of $25,200.00. Following the completion of the sale, the chief operating officer now owns 503,712 shares in the company, valued at approximately $906,681.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 29,000 shares of company stock valued at $51,075 in the last quarter. Insiders own 9.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Athersys (ATHX) Given Daily Coverage Optimism Score of 0.20” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/18/athersys-athx-given-daily-coverage-optimism-score-of-0-20.html.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply